Companies › Mediar Therapeutics
3 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 1; Metabolic and endocrine, Immunology, Respiratory; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MTX-463 IgG1 monoclonal antibody directed against WNT-inducible signaling pathway protein 1 (WISP1 | WISP1 | Phase 2 | Idiopathic Pulmonary Fibrosis | Aug 2027 |
| MTX-474 anti-EphrinB2 monoclonal antibody | EFNB2 | Phase 2 | Diffuse Cutaneous Systemic Sclerosis | Dec 2028 |
| MTX-439 Anti-SMOC2 monoclonal antibody | SMOC2 | Phase 1 | Healthy Adult Participants | May 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07473323 | MTX-439 | Phase 1 | Healthy Adult Participants | Metabolic and endocrine | May 2027 |
| NCT06967805 | MTX-463 | Phase 2 | Idiopathic Pulmonary Fibrosis | Respiratory | Aug 2027 |
| NCT07287670 | MTX-474 | Phase 2 | Diffuse Cutaneous Systemic Sclerosis | Immunology | Dec 2028 |
Hangzhou Sciwind Biosciences Arcturus Therapeutics Direct Biologics Genrix (Shanghai) Biopharmaceutical Bluefin Biomedicine
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.